Experimental evaluation of inactivated and live attenuated vaccines against Mycoplasma mycoides subsp. mycoides

Veterinary Immunology and Immunopathology
Martin MwirigiHezron Wesonga

Abstract

The current control method for contagious bovine pleuropneumonia (CBPP) in Africa is vaccination with a live, attenuated strain of Mycoplasma mycoides subsp. mycoides (Mmm). However, this method is not very efficient and often causes serious adverse reactions. Several studies have attempted to induce protection using inactivated mycoplasma, but with widely contradictory results. Therefore, we compared the protective capacity of the live T1/44 vaccine with two inactivated preparations of Mmm strain Afadé, inoculated with an adjuvant. Protection was measured after a challenge with Afadé. The protection levels were 31%, 80.8% and 74.1% for the formalin-inactivated, heat-inactivated and live attenuated preparations, respectively. These findings indicate that low doses of heat-inactivated Mmm can offer protection to a level similar to the current live attenuated (T1/44) vaccine formulation.

References

Feb 1, 1988·Tropical Animal Health and Production·G L MuliraE Nandokha
Jun 18, 2003·Preventive Veterinary Medicine·L J M Kusiluka, F F Sudi
Nov 25, 2003·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·O J B HübschleB Morein
Jun 22, 2010·Tropical Animal Health and Production·Isabel Gacheri NkandoDeclan McKeever

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.